Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Business Achievements

Lupin Announces New Center of Excellence for Inhalation Research in Florida

Friday, August 07, 2015   (0 Comments)
Share |

Mumbai, August 7, 2015: Pharma Major Lupin Limited (Lupin) today announced the opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Local and state leaders, including Florida Lieutenant Governor Carlos Lopez-Cantera, Florida Department of Economic Opportunity Director Jesse Panuccio, and Mayor Skip Campbell, were on site to celebrate the opening of Lupin's new facility with a ribbon cutting ceremony. Bringing 45 highly skilled positions to Broward County, Lupin's South Florida expansion recognizes the steady growth of Florida's life sciences industry and the economic potential it holds for the state. Lupin's new facility will focus on the research and development of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases. "We are delighted to be making our mark in South Florida," said Vinita Gupta, CEO, Lupin Limited. "With the talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally. The new inhalation research and development facility is a significant step forward in our journey to emerge as a global specialty pharmaceutical player."

"Lupin's Coral Springs expansion further reinforces Florida's standing as the number one place to do business," said Florida Lt. Governor Carlos Lopez-Cantera. "The opening of this facility is a testament to the strength of Florida's life sciences industry and the diverse and talented workforce who call this state home. We welcome Lupin to the Sunshine State and look forward to the incredible research and therapies that are developed as a result of their presence in Florida."

Lupin's Coral Springs facility was made possible through collaboration among Enterprise Florida, the Florida Department of Economic Opportunity, CareerSource Florida, Broward County and the Greater Fort Lauderdale Alliance..

Florida Department of Economic Opportunity Executive Director Jesse Panuccio said, "The official opening of Lupin Inc. is great news for the City of Coral Springs and the Florida economy. The Scott administration's pro- growth policies are fostering Florida's emergent life sciences sector, as companies like Lupin continue to create high-wage, high-skill employment opportunities."

"The City of Coral Springs is excited to welcome Lupin," said City of Coral Springs Mayor Skip Campbell. "Our community is well positioned to support world-class companies, like this one, and we look forward to playing a role in their continued growth and success."

"Lupin's grand opening in Broward County is an example of how our area is creating, attracting and expanding high-wage jobs," said Bob Swindell, President and CEO of the Greater Fort Lauderdale Alliance. "The company's South Florida presence strengthens our state's robust life sciences industry cluster and we wish them every success."

About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were 125,997 million (USD 2.06 billion) and 24,032 million (USD 393 million) respectively. Please visit for more information.

About Aenova Group
The Aenova Group is one of the world's largest providers of services covering the entire value chain for the development and production of all the main dosage forms and product groups in the field of medicines and dietary supplements. As the European business-to-business market leader, the Aenova Group focuses on high standards of quality, innovative technologies and a clear vision for the future. The group operates overall 29 locations in eleven countries and employs more than 4700 people.

You could also follow us on Twitter

CIN:L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.

For further information or queries please contact

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555


Alpesh Dalal
Head - M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511

BioFlorida, Inc. | 901 NW 35th Street | Boca Raton, FL 33431
(P) 561-653-3839 (F) 561-653-3840
Membership Management Software Powered by®  ::  Legal